Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

Journal of Clinical Pharmacology

Volumn 36, Issue 8, 1996, Pages 728-731

  Posvar, Edward L ^a   Radulovic, Louis L ^a   Cilla Jr , Donald D ^a   Whitfield, Lloyd R ^a   Sedman, Allen J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COMPARISON; DRUG HALF LIFE; DRUG SOLUTION; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; NEUROTOXICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL;

EID: 0029794595     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04242.x     Document Type: Article

References (8)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. Shaw MK, Sliskovic DR, Roth B, Newton R, Krause BR: Hep-G2 cells resemble fibroblasts but not primary rat hepatocytes in their response to inhibition of HMG-CoA reductase (abstract 1546). FASEB J 1990;4:A533.
3. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS: CI-981 is superior to lovastatin for lowering plasma triglycerides in experimental animals (abstract 3289). FASEB J 1993;7:A567.
4. Newton RS, Krause BR, Stanfield RL, Bocan TMA, Shaw MK, Ferguson E, et al: Pharmacologic profile of PD 134298-38A, a novel HMG-CoA reductase inhibitor (abstract 552). Abstracts of the Tenth International Symposium on Drugs Affecting Lipid Metabolism. November 8-11, 1989.
5. Davignon J, Montigny M, Dufour R: HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843-864.
6. Smellie WAS, Lorimer AR: Adverse effects of the lipid-lowering drugs. Adverse Drug React Toxicol Rev 1992;11:71-92.
7. Ditschuneit HH, Kuhn K, Ditschuneit H: Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1991;40(suppl):S27-S32.
8. Rosenson RS, Goranson NL: Lovastatin-associated sleep and mood disturbances. Am J Med 1993;95:548-549.